Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | CD38 | P28907 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LSS | P48449 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16133619 | 1.00 | CYP2D6 (0.33) | CYP2D6HRH1KCNH2PIK3CDPDE7A | |
| SCHEMBL15700575 | 1.00 | CYP2D6 (0.33) | CYP2D6HRH1KCNH2PIK3CDPDE7A | |
| SCHEMBL3436793 | 0.91 | — | — | |
| Hydrochloric Acid SCHEMBL4349290 | 0.89 | PIK3CD (0.37) | CYP2D6HRH1KCNH2PIK3CDPDE7A | |
| SCHEMBL18742835 | 0.86 | LSS (0.39) | LSS | |
| SCHEMBL20160908 | 0.85 | PIK3CD (0.34) | CYP2D6HRH1KCNH2PIK3CDPDE7A | |
| SCHEMBL3436790 | 0.85 | PIK3CD (0.37) | CYP2D6HRH1KCNH2PIK3CDPDE7A | |
| SCHEMBL20160904 | 0.83 | KDM4E (0.37) | CYP2D6HRH1KCNH2PIK3CDPDE7A | |
| SCHEMBL18878200 | 0.83 | ACHE (0.37) | CYP2D6HRH1KCNH2PIK3CDPDE7A | |
| SCHEMBL24778488 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3512842-B1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS INC (US) | 2024-01-17 | — | — | EP | disclosed |
| US-11814373-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814373-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230312539-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230312539-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | disclosed |
| EP-3689868-B1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS INC (US) | 2023-09-27 | — | — | EP | disclosed |
| WO-2023142754-A1 | EZH1/2 INHIBITOR, PREPARATION THEREOF, AND USE THEREOF IN ANTI-TUMOR THERAPY | 江苏天士力帝益药业有限公司 | 2023-08-03 | — | — | WO | disclosed |
| WO-2022109426-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| EP-3950682-A1 | PREPARATION METHOD FOR AMIDE COMPOUNDS AND USE THEREOF IN MEDICAL FIELD | Shanghai Synergy Pharmaceutical Sciences Co., Ltd (CN) | 2022-02-09 | — | — | EP | disclosed |
| EP-3950676-A1 | PREPARATION METHOD FOR AMIDE COMPOUND AND APPLICATION THEREOF IN FIELD OF MEDICINE | Shanghai Synergy Pharmaceutical Sciences Co., Ltd (CN) | 2022-02-09 | — | — | EP | disclosed |
| US-20160024081-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. | 2016-01-28 | — | — | US | disclosed |
| US-9243001-B2 | Substituted benzene compounds | Epizyme, Inc. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150344427-A1 | 1,4-PYRIDONE COMPOUNDS | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344459-A1 | 1,4-PYRIDONE BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2015-12-03 | — | — | US | disclosed |
| US-20150284370-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2015-10-08 | — | — | US | disclosed |
| US-20150246916-A1 | Substituted 6, 5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. | 2015-09-03 | — | — | US | disclosed |
| US-20150246916-A1 | Substituted 6, 5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. | 2015-09-03 | — | — | US | disclosed |
| US-9045477-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140315945-A1 | Substituted Benzene Compounds | Epizyme, Inc. (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140296283-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. (US) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344459-A1 | 1,4-PYRIDONE BICYCLIC HETEROARYL COMPOUNDS | CYP4B1, PDXK, CYP1B1 | CYP2D6 25/4885HRH1 1072/4885KCNH2 2354/4885 |
| US-20150284370-A1 | SUBSTITUTED BENZENE COMPOUNDS | CYP1B1, TP53, VHL | CYP2D6 25/4885HRH1 1320/4885KCNH2 1223/4885 |
| US-20160024081-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | CYP3A5, PAICS, CYP4B1 | CYP2D6 8/4885HRH1 2066/4885KCNH2 2979/4885 |
| US-20230312539-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | CYP2D6 4086/4885HRH1 4616/4885KCNH2 4818/4885 |
| US-20150246916-A1 | Substituted 6, 5-Fused Bicyclic Heteroaryl Compounds | CYP3A5, PAICS, CYP4B1 | CYP2D6 8/4885HRH1 2066/4885KCNH2 2979/4885 |
| US-20150344427-A1 | 1,4-PYRIDONE COMPOUNDS | PDXK, PNPO, PLPBP | CYP2D6 165/4885HRH1 929/4885KCNH2 2147/4885 |
| US-20140296283-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | CYP3A5, PAICS, CYP4B1 | CYP2D6 8/4885HRH1 2066/4885KCNH2 2979/4885 |
| US-11814373-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | CYP2D6 4086/4885HRH1 4616/4885KCNH2 4818/4885 |
| US-20140315945-A1 | Substituted Benzene Compounds | VHL, AHR, TP53 | CYP2D6 34/4885HRH1 1726/4885KCNH2 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.